The cocktail product they advocate still has to stand up in a phase 3 trial - this funding news is a storm in a teacup .Their last phase 3 trial was unsuccessful.Meso is way ahead.
(NASDAQ: REGN) today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).
The cocktail product they advocate still has to stand up in a...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.050(4.26%) |
Mkt cap ! $1.295B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.19 | $1.12 | $9.136M | 8.018M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 88136 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 216607 | 10 |
View Market Depth
| Last trade - 14.38pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.13 |
Change
-0.050 ( 4.33 %) |
||||
| Open | High | Low | Volume | ||
| $1.17 | $1.17 | $1.12 | 1087100 | ||
| Last updated 14.59pm 08/05/2024 ? | |||||
| MSB (ASX) Chart |